| Entry |
|
|---|
| Name |
Cinacalcet hydrochloride (JAN/USAN);
Sensipar (TN);
Mimpara (TN) |
|---|
| Product |
|
|---|
| Generic |
CINACALCET (Accord Healthcare), CINACALCET (American Health Packaging), CINACALCET (Ascend Laboratories), CINACALCET (Aurobindo Pharma Limited), CINACALCET (Camber Pharmaceuticals), CINACALCET (Cipla USA), CINACALCET (Dr. Reddys Laboratories), CINACALCET (EXELAN PHARMACEUTICALS), CINACALCET (Golden State Medical Supply), CINACALCET (Lupin Pharmaceuticals), CINACALCET (Major Pharmaceuticals), CINACALCET (Mylan Pharmaceuticals), CINACALCET (NorthStar RxLLC), CINACALCET (Strides Pharma), CINACALCET (Strides Pharma Science Limited), CINACALCET (Sun Pharmaceutical Industries), CINACALCET (ACI Healthcare USA), CINACALCET HYDROCHLORIDE (Slate Run Pharmaceuticals) |
|---|
| Formula |
C22H22F3N. HCl
|
|---|
| Exact mass |
393.1471
|
|---|
| Mol weight |
393.8729
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 3999 |
| Product (DG00513): | D03505<JP/US> |
|
|---|
| Efficacy |
Antihypercalcemia, Antihyperparathyroidism, Calcium sensing receptor allosteric modulator |
|---|
| Disease |
Secondary hyperparathyroidism [DS: H01669] Parathyroid carcinoma [DS: H01558] Primary Hyperparathyroidism [DS: H00246] |
|---|
| Comment |
Treatment of hyperparathyroidism and related disorders, such as hypercalcemia (reduction of PTH secretion through modulation of calcium ion receptors on parathyroid cells)
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04621 | NOD-like receptor signaling pathway |
| hsa04928 | Parathyroid hormone synthesis, secretion and action |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
CYP inhibition: CYP2D6 [HSA: 1565]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
H05 CALCIUM HOMEOSTASIS
H05B ANTI-PARATHYROID AGENTS
H05BX Other anti-parathyroid agents
H05BX01 Cinacalcet
D03505 Cinacalcet hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Metabolic Bone Disease Agents
Calcium-sensing Receptor Agonist
Cinacalcet
D03505 Cinacalcet hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D03505 Cinacalcet hydrochloride (JAN/USAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Metabotropic glutamate receptor family
Calcium-sensing
CASR
D03505 Cinacalcet hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03505
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03505
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03505
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03505
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03505
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 27
1 C8x C 14.3657 -13.4461
2 C8y C 14.3657 -14.8469
3 C8y C 15.5788 -15.5473
4 C8y C 16.7920 -14.8469
5 C8x C 16.7920 -13.4461
6 C8x C 15.5788 -12.7457
7 C8x C 13.1526 -15.5473
8 C8x C 13.1526 -16.9481
9 C8x C 14.3657 -17.6485
10 C8x C 15.5788 -16.9481
11 C1c C 18.0302 -15.5473
12 N1b N 19.2433 -14.8469
13 C1b C 20.4564 -15.5473
14 C1b C 21.6695 -14.8469
15 C1b C 22.8828 -15.5473
16 C1a C 18.0365 -16.9620
17 C8y C 24.0711 -14.8611
18 C8x C 25.2666 -15.5514
19 C8y C 26.4808 -14.8505
20 C8x C 26.4809 -13.4486
21 C8x C 25.2853 -12.7582
22 C8x C 24.0711 -13.4592
23 C1d C 27.7137 -15.5624
24 X F 28.9108 -16.2538
25 X F 28.4104 -14.3558
26 X F 27.0085 -16.7838
27 X Cl 32.4800 -15.4700
BOND 28
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 2 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 3 10 1
12 4 11 1
13 11 12 1
14 12 13 1
15 13 14 1
16 14 15 1
17 11 16 1 #Down
18 15 17 1
19 17 18 2
20 18 19 1
21 19 20 2
22 20 21 1
23 21 22 2
24 17 22 1
25 19 23 1
26 23 24 1
27 23 25 1
28 23 26 1
|
|---|
